基因工程生物制剂治疗强直性脊柱炎患者葡萄膜炎（临床观察）。
Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations).
机构信息
Research Institute of Eye Diseases, Moscow, Russia.
Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
出版信息
Vestn Oftalmol. 2022;138(3):68-72. doi: 10.17116/oftalma202213803168.
PMID:35801883
Abstract
The article describes clinical cases with effective use of some genetically engineered biological agents for arresting and preventing uveitis attacks, and discusses the potential usage of tumor necrosis factor (TNF)-alpha inhibitors and interleukin-17 inhibitors in the treatment of uveitis in patients with ankylosing spondylitis.
摘要
文章描述了一些基因工程生物制剂在控制和预防葡萄膜炎发作方面的有效临床应用案例，并探讨了肿瘤坏死因子（TNF）-α抑制剂和白细胞介素-17 抑制剂在强直性脊柱炎患者葡萄膜炎治疗中的潜在应用。
Zotero 插件